中外女性健康研究2024,Issue(7) :50-52.

抗HER2乳腺癌ADC药物研究进展

Research progress of anti-HER2 breast cancer ADC drugs

迟曰梅 周涛
中外女性健康研究2024,Issue(7) :50-52.

抗HER2乳腺癌ADC药物研究进展

Research progress of anti-HER2 breast cancer ADC drugs

迟曰梅 1周涛1
扫码查看

作者信息

  • 1. 日照市人民医院乳腺甲状腺外科,山东日照 276800
  • 折叠

摘要

乳腺癌发病率居女性恶性肿瘤首位,其是由于乳腺上皮细胞发生增殖失控,进而恶变.在乳腺癌治疗时,抗人表皮生长因子受体2(HER2)乳腺癌抗体药物耦联物(ADC)的应用逐渐受到重视,本文就对乳腺癌治疗中常用的抗HER2乳腺癌ADC药物(恩美曲妥珠单抗、德曲妥珠单抗、曲妥珠单抗多卡马嗪、维迪西妥单抗、MM-302、XMT-1522、ARX788、MEDI4276)的应用效果进行综述,以期为抗HER2乳腺癌ADC药物的合理应用提供参考.

Abstract

The incidence of breast cancer ranks first among female malignant tumors,which is due to the uncontrolled prolifer-ation of breast epithelial cells,and then malignant transformation.In the treatment of breast cancer,the application of anti-hu-man epidermal growth factor receptor 2(HER2)breast cancer antibody drug conjugate(ADC)has been paid more and more at-tention,in this paper,the anti-HER2 breast cancer ADC drugs commonly used in the treatment of breast cancer(enmetrastu-zumab,trastuzumab,trastuzumab,trastuzumab dokamazin,vidicetuzumab,MM-302,XMT-1522,ARX788,MEDI4276)were reviewed in order to provide reference for the rational application of anti-HER2 breast cancer ADC drugs.

关键词

乳腺癌/人表皮生长因子受体2/抗体药物耦联物/恩美曲妥珠单抗

Key words

Breast cancer/Human epidermal growth factor receptor 2/Antibody-drug conjugate/Enmetrastuzumab

引用本文复制引用

出版年

2024
中外女性健康研究
武汉大学

中外女性健康研究

ISSN:2096-0417
段落导航相关论文